Please check your internet connection and try again.
# Ticagrelor
## Overview
Ticagrelor is a direct-acting, reversible P2Y12 receptor antagonist used to prevent thrombotic events.
## Primary Indications
* In combination with aspirin for the prevention of thrombotic events in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI).
## Adult Dosing
* **ACS:** 180 mg orally once as a single loading dose, followed by 90 mg orally twice daily.
* **Post-MI (secondary prevention):** After at least 1 year of treatment with ticagrelor 90 mg twice daily for ACS, the dose may be reduced to 60 mg orally twice daily, provided the patient is at high risk for ischemic events and low risk for bleeding.
## Pediatric Dosing
* No established pediatric dosing.
## Dose Adjustments
* **Renal Impairment:** No dose adjustment required.
* **Hepatic Impairment:** No dose adjustment required. However, caution is advised in severe hepatic impairment due to lack of data.
## Contraindications
* Active bleeding.
* History of transient ischemic attack (TIA) or stroke.
* Known hypersensitivity to ticagrelor or any of its components.
## Adverse Effects
* **Most Common:** Dyspnea, bradycardia, ventricular pauses.
* **Serious:** Bleeding (major and minor), intracranial hemorrhage, hypotension.
## Key Drug Interactions
* **Strong CYP3A4 Inhibitors (e.g., ketoconazole, clarithromycin, ritonavir):** Can increase ticagrelor exposure and risk of bleeding. Avoid coadministration or use with caution, potentially reducing ticagrelor dose.
* **Strong CYP3A4 Inducers (e.g., rifampin, carbamazepine, phenytoin):** Can decrease ticagrelor exposure. Avoid coadministration.
* **CYP2C19 Substrates (e.g., omeprazole):** Ticagrelor is a CYP2C19 inhibitor. Concurrent use with high-dose omeprazole may increase ticagrelor plasma concentrations. Consider alternative proton pump inhibitors (e.g., pantoprazole).
* **Aspirin:** Recommended for use in combination with ticagrelor in ACS. Long-term use of ticagrelor alone without aspirin is for specific secondary prevention scenarios.
* **Statins:** Increased risk of hypercholesterolemia.
## Monitoring
* Monitor for signs and symptoms of bleeding.
* Monitor for bradycardia and other ECG changes.
## Clinical Pearls
* Ticagrelor should be initiated as soon as possible in patients with ACS, regardless of whether they are managed medically or invasively.
* The 90 mg twice-daily dose is typically used for 1 year in ACS patients, then can be reduced to 60 mg twice-daily in select high-risk patients.
* Patients should be advised not to stop ticagrelor prematurely, as this increases the risk of thrombotic events.
* Ticagrelor is a reversible antagonist, allowing for faster platelet function recovery compared to clopidogrel if urgent surgery is needed.
* Dyspnea is a common side effect and may be related to bradycardia or other mechanisms; it usually resolves and does not require discontinuation.
***
*Please verify the current prescribing information for the most up-to-date and complete details.*
